ABSTRACT: Fengycins are cyclic lipo-depsipeptides produced by Bacillus spp. that display potent antifungal properties but are chemically unstable. This instability has meant that no total synthesis of any fengycin has been published. Here we report the synthesis of fengycin A analogues that display enhanced antifungal properties and chemical stability under both basic and acidic conditions. The analogues prepared also demonstrate that the fengycin core structure can be modified and simplified without the loss of antifungal activity.

Plant pathogens, and in particular fungal diseases, pose an increasing risk to global food security.1−3 An important part of the crop protection arsenal is Bacillus subtilis strains, which are used as biological control agents (BCAs) (Serenade).4−6 Bioactive Bacillus spp. are able to secrete, as an innate response to external microbiota stimuli, potent antimicrobial metabolites that include the cyclic lipopeptides (CliPs) from the iturin, surfactin, and fengycin families (Figure 1).5,7−13 Fengycins are the dominant CliPs in Bacillus spp.5,14,15 and are active against a range of phytopathogenic fungi12,16−19 causing cell lysis and leakage through binding with the plasma membrane.

While most research on BCAs has focused on the direct application of live bacteria, the effects of a range of environmental factors (i.e., soil type and humidity) can produce broad inconsistencies in their performance within the field.20 A further disadvantage relates to the fact that antifungal BCAs act slowly when compared to typical pests, and therefore only give a very time-limited protection to crops.21 In light of these factors the application of individual bioactive CliPs, rather than the entire living organisms, would be an attractive option for the development of new crop protection agents. However, the problem with this strategy is that isolation and/or chemical synthesis of certain CliPs, like fengycin, has proven to be challenging.

Contrary to iturins and surfactins, fengycins display a hydrolytically susceptible aromatic depsipeptide bond between Tyr^3 and Ile^10 which significantly compromises the structural integrity of its cyclic core (Figure 1A).22,23 This intrinsic lack of chemical stability means that fengycins are technically challenging to prepare via chemical synthesis.24,25 This is
clearly highlighted by the fact that to date no synthetic strategy has succeeded in delivering a completely natural fengycin peptide and, only very recently, a solid phase peptide synthesis (SPPS) approach which enabled the synthesis of several fengycin analogues was reported.\(^{26}\) While this marked a significant advance for the field, the reported approach only afforded modest product yields and it did not address the issue of the fengycin peptides’ innate instability.

To address the challenges associated with both the synthesis and stability of fengycins, we proposed to prepare a series of modified and simplified analogues (Figure 1B). To solve the issue of its chemical stability we hypothesized that fengycin derivatization into a lactam-bridged cyclopeptide, rather than through its natural ester functionality, would enable access to more stable cyclic analogues. This approach has been shown previously in the literature to help improve the chemical stability of a range of cyclic peptides.\(^ {27−29}\) Second, in order to simplify and reduce the associated cost of the synthesis we sought to replace the \(\beta\)-allo-Thr residue at position \(R_4\) and also remove the chiral hydroxyl center from the lipid tail. Herein, we report an efficient SPPS route that allows ready access to fengycin A analogues with enhanced antifungal and chemical stability when compared to the natural product.

Not constrained by the limitations imposed by the natural depsipeptide bridge, we sought to design possible SPPS routes that could achieve efficient cyclization yields and enable flexible peptide diversification on resin (Figures 2 and 3). We hypothesized that a strategy based on an early stage peptide cyclization, rather than a late-stage peptide macrolactamization, would be beneficial due to the lower conformational flexibility of the peptide chain, allowing for increased linear to cyclic product conversions.

On this basis, we first designed a synthetic route for the cyclic core, using a Fmoc-\(/(\text{Bu}/\text{Boc})/\text{Dmb}\) protection scheme, that could take advantage of the presence of a natural \(i\)-Gln residue in the peptide structure to install a side-chain anchor to the resin (Figure 2). Under this strategy, Fmoc-Glu(OH)-ODmab (1) is thus attached in the first step of the synthesis to the Rink-amide resin. Dmb protection was selected as it is orthogonal to base-labile Fmoc and acid-labile \(\text{Bu}/\text{Boc}\) protecting groups and its selective removal can proceed quantitatively in the presence of hydrazine (2-5\% \(v/v\) in DMF).\(^ {30}\) Other options, such as allyl esters, have proven on occasion in our hands to be difficult to deprotect.\(^ {31,32}\)

To test the suitability of this approach, we synthesized model peptidyl-resin 5 following standard Fmoc-\(/\text{Bu}\) chemistry procedures. Peptide 5 mimics the sequence of the fengycin cyclic domain but for the \(^ {3}\)Tyr\(^ {10}\)Ile depsipeptide bridge, which was replaced for an amide bond linkage by using Boc-4-(Fmoc-amino)-l-phenylalanine (3) (Figure 2A, see Supporting Information for complete experimental details). Then, we proceeded to evaluate the efficiency of the intramolecular cyclization step (Figure 2B,C). For this, 5 was incubated overnight in the presence of DIC/HOBt (3 mol equiv each; \(rt\)) and sample aliquots of the resins before (5) and after cyclization (6) cleaved in the presence of TFA/H\(_2\)O/TIPS, 95:2.5:2.5\% \(v/v/v\). Satisfyingly, analysis of the crude materials by LC/(ESI\(^ +\))MS spectrometry at \(\lambda = 254\) nm, characteristic of the aromatic residues present, confirmed quantitative version of the linear peptide 5 (m/z = 983.6 \(Da\), \(t_b = 1.1\) min; [\(M + H\)]\(^ +\)); Figure 2B) to the expected cyclic product 6 (m/z = 965.7 \(Da\), \(t_b = 1.4\) min; [\(M + H\)]\(^ +\)); Figure 2C).

Next, we turned our attention to addressing the complexity of the branched fengycin structure (Figure 3). For this, peptidyl-resin 2 was resynthesized and the peptide sequence extended until the key residue where the peptide bifurcates (10, Figure 3B). At this critical point, we had anticipated the need for a protected 4Ap derivative that could enable both the temporal protection of the peptidyl-resin N-terminus and the controlled propagation and ring closure of the peptide through its aniline functionality.

We also considered that such a derivative must allow for subsequent peptide Ct → \(Nt\) elongation by means of conventional Fmoc amino acids, to prevent posterior racemization and to minimize the need for custom-made materials. Chemical orthogonality to the Rink-amide C-terminus, side chain Boc/\(\text{Bu}\), and Dmb protecting groups was also needed in the protecting group approach selected. Given the aforementioned factors we opted to synthesize the NtTrityl/NFmoc protected amino acid Trt-\(i\)-4(NFmoc)Aph-OH (9, Figure 3A).

As described, in Figure 3A, amino acid 9 could be synthesized in 4 steps from its commercially available Boc-4-(Fmoc-amino)-l-phenylalanine precursor (3). First, the carboxylic functionality in 3 was converted to its allyl ester using \(K_2\)CO\(_3\) (1 mol equiv) and allyl bromide (1.5 mol equiv).\(^ {33}\) Next, the Boc group was removed in TFA (20\% \(v/v\) in DCM) and the Trt protection of the N-terminus achieved by slow addition of DIPEA (4 mol equiv) and Trt-Cl (1.5 mol equiv) in \(\text{CH}_2\text{CN}/\text{DCM} 2:1\). Lastly, selective removal of the allyl protecting group in 8 with Pd(PPh\(_3\))\(_4\) and PhSiH\(_3\) in DCM afforded the expected Trt-\(i\)-4(NFmoc)Aph-OH (9) with sufficient purity that it could be readily incorporated into
the peptide synthesis without any further purification (see Supporting Information for further details). Once 9 was coupled to the growing sequence, 11 was further elongated using standard procedures to yield target peptide 13, which was then cyclized in situ (Figure 3B).

With the fengycin cyclic core in hand, we then proceeded to complete the lipidated N-terminus. For this, the Trityl group in 14 was removed using a diluted solution of TFA/TIPS in DCM (0.2/1% v/v, 1 min, 5×) and the resulting peptide neutralized in DIPEA/DMF (5% v/v, 60 min). d-Orn (2.5 equiv) and L-Glu (5 equiv) were then sequentially incorporated via DIC/HOBt assisted couplings to complete the synthesis of the peptide component of the target. Finally, incorporation of the lipid tail was achieved by acylation of Fmoc deprotected resin (16) with palmitoyl chloride in the presence of DIPEA.

Gratifyingly, when the corresponding peptidyl-resin was cleaved we obtained the fengycin analogue 17A (crude yield of ~50%; Figure 3C). It is worth noting that, as seen in the cyclization of test peptide 5, no significant traces of the linear peptide or dimeric species could be found upon analysis of the crude material.22 The only byproduct observed was a d-Orn depleted analogue produced after cyclization due to the modest excess of this amino acid employed during the synthesis (21%, [M-114] Da, Figure 3; see also supporting Figures S19−20).

Similar or improved results were obtained when this methodology was employed to prepare 17B−17D, where we replaced the initial d-Thr residue at position 4 by the fengycin A naturally occurring d-allo-Thr and also their corresponding enantiomers (Figure 3C). Previous reports have shown that the chirality of the residues within the cyclic core of natural fengycin affects the ease of ring formation.22 However, our results in the synthesis of analogues 17B and 17D, using L-amino acids, show that this is not the case for fengycin lactam derivatives, as all of them could be synthesized with similar...
overall efficacy (50−70% crude purities, Figure 3C and Figures S23−S29). Overall, the synthesis of 17A−D clearly demonstrates the suitability of our synthetic approach for the convenient SPPS of fengycin cyclic lipopeptide amide analogues.

With peptides 17A−D prepared, we moved to investigate the differences in their chemical stability in comparison to that of the natural product. To this end, biosynthetic fengycin expressed from Bacillus spp. was purified by RP-HPLC and the major product, C16-fengycin B, was isolated and characterized (see Figures S32−S36). Hydrolysis studies were carried out with this compound due to the challenges in isolating enough pure fengycin A. We then selected hydrolysis conditions for our stability studies (50 mM NaOH for basic hydrolysis and 50% v/v TFA/H2O for acidic degradation; see Supporting Information for details).

When natural fengycin (C16-fengycin B) was incubated at room temperature in the presence of 50 mM NaOH, complete peptide degradation was observed within 5 min (Figure S37). In comparison, all of the amide-based fengycins analogues were found to be remarkably stable under the same conditions even for periods as long as 18−24 h (76−90% intact peptide, see Figures S39, S41, S43, S45). Acidolytic hydrolysis in the presence of TFA also revealed significantly different degradation profiles for the natural product (complete degradation in 12 h; Figure S38) when compared to the modified amide-bridged analogues (75−90% intact peptide, Figures S40, S42, S44, S46). The results obtained highlight the superior chemical stability exhibited by all of the amide analogues of fengycin. They also demonstrate that modification of the labile natural depsi Tyr3-O-Ile10 ester bond is a useful route by which to enhance the half-life of this family of bioactive molecules.

While the enhanced chemical stability of the fengycin analogues was welcomed, it was expected that the change to a lactam bridge would impact the biological activity; thus, bioassays were conducted to examine the effect of 17A−D on the growth of the fungus Fusarium graminearum. This fungus was selected as it is known to be sensitive to the natural lipopeptide.34 Figure 4 shows the results from growth measurements in well-plates in the absence and presence of the natural and synthetic fengycins.

The results presented in Figure 4 show that the synthetic fengycins (17A−D) inhibited growth to a much greater degree than natural fengycin isolated from Bacillus CS93. In fact, 17D was found to completely inhibit fungal growth.

In conclusion, we have developed an efficient synthetic route for the preparation of lactam-containing fengycin analogues. Given its modular approach and compatibility with readily available Fmoc amino acids, this method can be easily adapted to give access to a range of new fengycin derivatives. The fengycin analogues prepared in this study displayed enhanced antifungal properties over the naturally occurring material. Importantly, in addition to the enhanced antifungal properties, replacement of the natural depsi-bridge by an amide-bond linkage was found to significantly enhance their chemical stability under both basic and acidic conditions. Finally, this work demonstrates that the fengycin core structure could be modified (e.g., via amino acid substitution) and the lipid tail structure simplified without the loss of antifungal activity. This discovery combined with the SPPS approach reported herein will offer new opportunities to further develop this class of molecules as anti-infective agents for applications in both medicine and agriculture.

**ASSOCIATED CONTENT**

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.orglett.1c01387.

Experimental procedures, product characterization, HPLC stability studies data, and microbiological experimental description (PDF)

**AUTHOR INFORMATION**

Corresponding Author

Steven L. Cobb — Department of Chemistry, Durham University, Durham DH1 3LE, United Kingdom; orcid.org/0000-0002-3790-7023; Email: s.l.cobb@durham.ac.uk

Authors

Diana Gimenez — Department of Chemistry, Durham University, Durham DH1 3LE, United Kingdom
Aoiic Phelan — School of Biomolecular and Biomedical Science, University College Dublin, Dublin 4, Ireland
Cormac D. Murphy — School of Biomolecular and Biomedical Science, University College Dublin, Dublin 4, Ireland; orcid.org/0000-0002-2137-3338

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.orglett.1c01387

Notes

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This publication has emanated from research conducted with the financial support of Science Foundation Ireland under the Grant Number SFI/17/BBSRC/3417 and the BBSRC under Grant Reference BB/P022189/1.

**REFERENCES**

1. Bhattacharya, S. Deadly New Wheat Disease Threatens Europe’s Crops. Nature 2017, 542 (7640), 145.
2. Butler, D. Fungus Threatens Top Banana. Nature 2013, 504 (7479), 195.
3. Paini, D. R.; Sheppard, A. W.; Cook, D. C.; Barro, P. J. D.; Worner, S. P.; Thomas, M. B. Global Threat to Agriculture from 2017, 542 (7640), 145.

Figure 4. Effect of natural and synthetic fengycins on the growth of Fusarium graminearum. Fungal growth was measured in the absence (control) or presence of 500 μg/mL fengycin. t tests confirmed that all differences between natural and synthetic fengycins were significant (p < 0.05).
Invasive Species. *Proc. Natl. Acad. Sci. U. S. A.* 2016, 113 (27), 7575–7579.

(4) Cawoy, H.; Bettiol, W.; Fickers, P.; Ongena, M. Bacillus-Based Biological Control of Plant Diseases. In *Pesticides in the Modern World—Pesticides Use and Management*; IntechOpen, 2011.

(5) Ongena, M.; Jacques, P. Bacillus Lipopeptides: Versatile Weapons for Plant Disease Biocontrol. *Trends Microbiol.* 2008, 16 (3), 115–125.

(6) Jacobsen, B. J.; Zidack, N. K.; Larson, B. J. The Role of Bacillus-Based Biological Control Agents in Integrated Pest Management Systems: Plant Diseases. *Phytopathology* 2004, 94 (11), 1272–1275.

(7) Chen, H.; Wang, L.; Su, C. X.; Gong, G. H.; Wang, P.; Yu, Z. L. Isolation and Characterization of Lipopeptide Antibiotics Produced by Bacillus Subtilis. *Lett. Appl. Microbiol.* 2008, 47 (3), 180–186.

(8) Maget-Dana, R.; Thimon, L.; Peypoux, F.; Ptak, M. Surfactin/Iturin A Interactions May Explain the Synergistic Effect of Surfactin on the Biological Properties of Iturin A. *Biochimie* 1992, 74 (12), 1047–1051.

(9) Cawoy, H.; Debois, D.; Franzil, L.; Pauw, E. D.; Thonart, P.; Ongena, M. Lipopeptides as Main Ingredients for Inhibition of Fungal Phytopathogens by Bacillus Subtilis/Amphioyloqueficiens. *Microb. Biotechnol.* 2015, 8 (2), 281–295.

(10) Peypoux, F.; Bonnamin, J. M.; Wallach, J. Recent Trends in the Biochemistry of Surfactin. *Appl. Microbiol. Biotechnol.* 1999, 51 (5), 553–563.

(11) Yu, G. Y.; Sinclair, J. B.; Hartman, G. L.; Bertagnoli, B. L. Production of Iturin A by Bacillus Amphioyloqueficiens Suppressing Rhizoctonia Solani. *Soil Biol. Biochem.* 2002, 34 (7), 955–963.

(12) Ongena, M.; Jacques, P.; Tourné, Y.; Destain, J.; Jabrane, A.; Thonart, P. Involvement of Fengycin-Type Lipopeptides in the Multifaceted Biocontrol Potential of Bacillus Subtilis. *Appl. Microbiol. Biotechnol.* 2005, 69 (1), 29.

(13) Razafindralambo, H.; Popineau, Y.; Deleu, M.; Hbid, C.; Jacques, P.; Thonart, P.; Paquot, M. Surface-Active Properties of Surfactin/Iturin A Mixtures Produced by Bacillus Subtilis. *Langmuir* 1997, 13 (23), 6026–6031.

(14) Maget-Dana, R.; Peypoux, F. Iturins, a Special Class of Pore-Forming Lipopeptides: Biological and Physicochemical Properties. *Toxicology* 1994, 87 (1), 151–174.

(15) Zhao, H.; Shao, D.; Jiang, C.; Shi, J.; Li, Q.; Huang, Q.; Rajoka, M. S. R.; Yang, H.; Jin, M. Biological Activity of Lipopeptides from Bacillus. *Appl. Microbiol. Biotechnol.* 2017, 101 (15), 5951–5960.

(16) Vanitnantakom, N.; Loeffler, W.; Koch, U.; Jung, G. Fengycin-A Novel Antifungal Lipopeptide Antibiotic Produced by Bacillus Subtilis F-29–3. *J. Antibiot.* 1986, 39 (7), 888–901.

(17) Romero, D.; de Vicente, A.; Rakootaey, R. H.; Dufour, S. E.; Veening, J.-W.; Arebola, E.; Cazorla, F. M.; Kuipers, O. P.; Paquot, M.; Pérez-García, A. The Iturin and Fengycin Families of Lipopeptides Are Key Factors in Antagonism of Bacillus Subtilis toward Podosphaera Fulva. *Mol. Plant-Microbe Interact.* 2007, 20 (4), 430–440.

(18) Ali, G. S.; El-Sayed, A. A. S.; Patel, J. S.; Green, K. B.; Ali, M.; Brennan, M.; Norman, D. *Ex Vivo* Application of Secreted Metabolites Produced by Soil-Inhabiting Bacillus Spp. Efficiently Controls Foliar Diseases Caused by Alternaria Spp. *Appl. Environ. Microbiol.* 2016, 82 (2), 478–490.

(19) (a) Zihalirwa Kulimushi, P.; Argüelles Arias, A.; Franzi, L.; Steels, S.; Ongena, M. Stimulation of Fengycin-Type Antifungal Lipopeptides in Bacillus Amphioyloqueficiens in the Presence of the Maize Fungal Pathogen Rhizomucor Variabilis. *Front. Microbiol.* 2017, 8, 850. (b) Kim, P. I.; Ryu, J.; Kim, Y. H.; Chi, Y. T. Production of biosurfactant lipopeptides Iturin A, fengycin and surfactin A from Bacillus subtilis CMB32 for control of *Colletotrichum gloeosporioides*. *J. Microbiol. Biotechnol.* 2010, 20 (1), 138–145.

(20) Weller, D. M.; Thomashow, L. S. Current Challenges in Introducing Beneficial Microorganisms into the Rhizosphere. In *Molecular Ecology of Rhizosphere Microorganisms*; John Wiley & Sons, Ltd., 2007; pp 1–18.

(21) Butt, T. M.; Copping, L. G. Fungal Biological Control Agents. *Pestic. Outlook* 2000, 11 (5), 186–191.

(22) Rosés, C.; Camó, C.; Vogels, K.; Planas, M.; Feliu, L. Solid-Phase Synthesis of Cyclic Depsipeptides Containing a Tyrosine Phenyl Ester Bond. *Org. Lett.* 2016, 18 (16), 4140–4143.

(23) Honma, M.; Tanaka, K.; Konno, K.; Tsuge, K.; Okuno, T.; Hashimoto, M. Termination of the Structural Confusion between Pilspastatin A1 and Fengycin IX. *Bioorg. Med. Chem.* 2012, 20 (12), 3793–3798.

(24) Sieber, S. A.; Mariheli, M. A. Learning from Nature’s Drug Factors: Nonribosomal Synthesis of Macroyclic Peptides. *J. Bacteriol.* 2003, 185 (24), 7036–7043.

(25) Sieber, S. A.; Tao, J.; Walsh, C. T.; Mariheli, M. A. Peptidyl Thiophenols as Substrates for Nonribosomal Peptide Cyclases. *Anorg. Chem., Int. Ed.* 2004, 43 (4), 493–498.

(26) Rosés, C.; Camó, C.; Oliveras, A.; Moll, L.; López, N.; Feliu, L.; Planas, M. Total Solid-Phase Synthesis of Dehydroxy Fengycin Derivatives. *J. Org. Chem.* 2018, 83 (24), 15297–15311.

(27) Barrett, D.; Tanaka, A.; Fujie, A.; Shigematsu, N.; Hashimoto, M.; Hashimoto, S. An Expedient Synthesis of the Amide Analog of the Potent Antifungal Lipopeptidolactone FR901469. *Tetrahedron Lett.* 2001, 42 (4), 703–705.

(28) Bionda, N.; Stawikowski, M.; Stawikowska, R.; Cudic, M.; López-Vallejo, F.; Treitl, D.; Medina-Franco, J.; Cudic, P. Effects of Cyclic Lipopeptide Structural Modulation on Stability, Anti-bacterial Activity, and Human Cell Toxicity. *ChemMedChem* 2012, 7 (5), 871–882.

(29) Bionda, N.; Pastar, I.; Davis, S. C.; Cudic, P. In Vitro and in Vivo Activities of Novel Cyclic Lipopeptides against Staphylococcal Biofilms. *Protein Pept. Lett.* 2014, 21 (4), 352–356.

(30) Conroy, T.; Jolliffe, K. A.; Payne, R. J. Efficient Use of the Dmb Protecting Group: Applications for the Solid-Phase Synthesis of N-Linked Glycopeptides. *Org. Biomol. Chem.* 2009, 7 (11), 2255–2258.

(31) Greico, P.; Gittu, P. M.; Hrubby, V. J. Preparation of ‘Side-Chain-to-Side-Chain’ Cyclic Peptides by Allyl and Alloc Strategy: Potential for Library Synthesis. *J. Pept. Res.* 2001, 57 (3), 250–256.

(32) Lear, S.; Munshi, T. K.; Hudson, A. S.; Hatton, C.; Clardy, J.; Mosely, J. A.; Bull, T. J.; Sit, C.-S.-W.; Cobb, S. L. Total Chemical Synthesis of Lassomycin and Lassomycin-Amide. *Org. Biomol. Chem.* 2016, 14 (19), 4534–4541.

(33) Crich, D.; Sana, K. Solid Phase Synthesis of Peptidyl Thioacids Employing a 9-Fluorenylmethyl Thioester-Based Linker in Conjunction with Boc Chemistry. *J. Org. Chem.* 2009, 74 (19), 7383–7388.

(34) Wang, J.; Liu, J.; Chen, H.; Yao, J. Characterization of Fusarium Gnaminearum Inhibitory Lipopeptide from Bacillus Subtilis IB. *Appl. Microbiol. Biotechnol.* 2007, 76 (4), 889–894.